Complications of colonoscopy

This is one of a series of position statements discussing the use of GI endoscopy in common clinical situations. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy prepared this text. In preparing this document, the authors performed a search of the medical literature by using PubMed. Additional references were obtained from the bibliographies of the identified articles and from recommendations of expert consultants. When limited or no data existed from well-designed prospective trials, emphasis was given to results from large series and reports from recognized experts. Position statements are based on a critical review of the available data and expert consensus at the time the documents are drafted. Further controlled clinical studies may be needed to clarify aspects of this document, which may be revised as necessary to account for changes in technology, new data, or other aspects of clinical practice.

This document is intended to be an educational device to provide information that may assist endoscopists in providing care to patients. This position statement is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment. Clinical decisions in any particular case involve a complex analysis of the patient’s condition and available courses of action. Therefore, clinical considerations may lead an endoscopist to take a course of action that varies from this position statement. This document is an update of the 2003 ASGE document entitled “Complications of colonoscopy.”

Colonoscopy is a commonly performed procedure for the diagnosis and treatment of a wide range of conditions and symptoms and for the screening and surveillance of colorectal neoplasia. Although up to 33% of patients report at least one minor, transient GI symptom after colonoscopy, serious complications are uncommon. In a 2008 systematic review of 12 studies totaling 57,742 colonoscopies performed for average risk screening, the pooled overall serious adverse event rate was 2.8 per 1000 procedures. The risk of some complications may be higher if the colonoscopy is performed for an indication other than screening. The colorectal cancer miss rate of colonoscopy has been reported to be as high as 6%, and the miss rate for adenomas larger than 1 cm is 12% to 17%. Although missed lesions are considered a poor outcome of colonoscopy, they are not a complication of the procedure per se and will not be discussed further in this document. Complications of bowel preparations are discussed in the American Society for Gastrointestinal Endoscopy Technology Status Evaluation Report for Colonoscopy Preparations.

Over 85% of the serious colonoscopy complications are reported in patients undergoing colonoscopy with polypectomy. An analysis of Canadian administrative data, including over 97,000 colonoscopies, found that polypectomy was associated with a 7-fold increase in the risk of bleeding or perforation. However, complication data are often not stratified by whether or not polypectomy was performed. Therefore, complications of polypectomy are discussed with those of diagnostic colonoscopy. A discussion of the diagnosis and management of all complications of colonoscopy is beyond the scope of this document, although general principles are reviewed.

CARDIOPULMONARY COMPLICATIONS

Cardiovascular and pulmonary complications related to sedation are reviewed in detail in the 2008 American Society for Gastrointestinal Endoscopy Guideline for Sedation and Anesthesia in GI Endoscopy. Intraprocedural cardiopulmonary complications have been variably defined to include events of unclear clinical significance, such as minor fluctuations in oxygen saturation or heart rate, to significant complications including respiratory arrest, cardiac arrhythmias, myocardial infarction, and shock. In a study that used the Clinical Outcomes Research Initiative (CORI) database, cardiopulmonary complications occurred in 0.9% of procedures and made up 67% of the unplanned events during or after endoscopic procedures with sedation. Transient hypoxemia occurred in 230 per 100,000 colonoscopies, but prolonged hypoxemia was reported in only 0.78 per 100,000 colonoscopies. Hypotension occurred in 480 per 100,000 colonoscopies. CORI data may underestimate acute complications because of missing data and underreporting. A 2008 systematic review of randomized, controlled trials of patients undergoing colonoscopy and/or EGD reported much higher cardiopulmonary event rates with a weighted rate of 6% to 11% for hypoxemia and 5% to 7% for hypotension, depending on the specific drug regimen used.
In addition to acute complications, colonoscopy is associated with an increased incidence of cardiovascular events in the 30-day postprocedure period. A study of Medicare beneficiaries reported an unadjusted rate of cardiovascular events requiring hospitalization or emergency department visits of 1030 per 100,000 procedures, which was significantly higher compared with matched controls (885/100,000 procedures). In a prospective study of patients undergoing colonoscopy at CORI sites, the event rate at 30 days was 1.4 per 1000 for angina, myocardial infarction, stroke, or transient ischemic attack.

It is known that the risk of cardiopulmonary events associated with colonoscopy is increased with advanced age, higher American Society of Anesthesiologists Physical Status Classification System scores, and the presence of comorbidities. Appropriate assessment of anesthesia risk prior to colonoscopy may reduce cardiopulmonary complications by ensuring that high-risk patients are co-managed with other specialists (eg, cardiology, anesthesiology). Appropriate monitoring before, during, and after the procedure also may reduce the risk of complications. Unstable patients should have non-emergent colonoscopy delayed as appropriate. In addition, continuing aspirin and other antiplatelet agents in the peri-endoscopic period may reduce the risk of cardiovascular events. The current American Society for Gastrointestinal Endoscopy Guideline for Management of Anti-thrombotic Agents for Endoscopic Procedures stresses that the risks of bleeding while receiving antithrombotic therapy must be weighed against the risks of a thrombotic event if that therapy is withheld. Although many thrombotic events may be devastating, procedure-related GI bleeding is usually manageable and infrequently associated with significant morbidity or mortality.

**PERFORATION**

Colonic perforation during colonoscopy may result from mechanical forces against the bowel wall, barotrauma, or as a direct result of therapeutic procedures. Early symptoms of perforation include persistent abdominal pain and abdominal distention. Later, patients may develop peritonitis. Plain radiographs of the chest and abdomen may demonstrate free air, although CT scans have been shown to be superior to the upright chest film. Therefore, an abdominal CT scan should be considered for patients with an unrevealing plain film in whom there is a high suspicion of perforation.

The rate of perforation reported in large studies is 0.3% or less and is generally less than 0.1%. In a large study of screening colonoscopy, perforation was reported in 13 of 84,412 procedures (0.01%). In a case-controlled study of 277,454 Medicaid beneficiaries undergoing colonoscopy, the rate of perforation was 8.2 per 10,000 procedures (0.08%) compared with 0.3 per 10,000 matched controls (0.003%). In a study analyzing over 50,000 colonoscopies and using Medicare claims data, the rate of perforation was 5 to 7 per 10,000 procedures (0.05%-0.07%) and not significantly different for procedures coded as screening without polypectomy, diagnostic without polypectomy, or with polypectomy (regardless of indication). Finally, in a large study of 116,000 patients undergoing colonoscopy at ambulatory endoscopy centers, there were 57 perforations (0.3%).

Surgical consultation should be obtained in all cases of perforation. Although perforation often requires surgical repair, nonsurgical management may be appropriate in select individuals. There is an increasing number of case reports demonstrating the feasibility of using endoscopic clipping devices to repair perforations.

There is evidence that performance of colonoscopy by an endoscopist with low procedure volume is associated with increased risk of perforation and bleeding. Creating a fluid cushion at the base or under large polyps in order to increase the degree of separation of the mucosal layers has been described as a technique to potentially reduce the risk of postpolypectomy perforation. It has been suggested that perforation rates greater than 1 in 500 for all colonoscopies or 1 in 1000 for screening colonoscopies should prompt evaluation of whether inappropriate practices are being used.

**HEMORRHAGE**

Hemorrhage is most often associated with polypectomy, although it can occur during diagnostic colonoscopy. When associated with polypectomy, hemorrhage may occur immediately or can be delayed for several weeks after the procedure. A number of large studies have reported hemorrhage in 1 to 6 per 1000 colonoscopies (0.1%-0.6%). A study analyzing over 50,000 colonoscopies by using Medicare claims found that the rate of GI hemorrhage was significantly different with or without polypectomy: 2.1 per 1000 procedures coded as screening without polypectomy and 3.7 per 1000 for procedures coded as diagnostic without polypectomy, compared with 8.7 per 1000 for any procedures with polypectomy. Polyp size has been reported as a risk factor for postpolypectomy bleeding in several studies. Additional risk factors may include the number of polyps removed, recent warfarin therapy, and polyp histology. Patient comorbidities, such as cardiovascular disease, may increase the risk for bleeding but also may be markers for anticoagulation use. Multiple, large studies did not find aspirin use associated with postpolypectomy bleeding. Another retrospective study found that concomitant use of either aspirin or nonsteroidal anti-inflammatory drugs and clopidogrel was an independent risk factor for bleeding, but aspirin or clopidogrel use alone was not. Recommendations for the management of antithrombotic therapy in the peri-endoscopic period are discussed in detail in another ASGE document.
The site of active bleeding can be identified endoscopically, through red blood cell nuclear scintigraphy, or angiographically. Acute postpolypectomy hemorrhage often is immediately apparent and amenable to endoscopic therapy. Nonendoscopic treatment modalities include angiographic embolization and surgery.

Using mini-snare resection without electrocautery instead of hot-biopsy forceps for removal of diminutive polyps may reduce bleeding. The prophylactic use of mechanical methods, such as clips or detachable snares has been reported. A randomized, controlled trial of prophylactic, detachable snare placement prior to polypectomy in 89 patients with large, pedunculated polyps found a significant reduction in bleeding in the detachable snare group (0% vs 12%). The placement of endoscopic clips after removal of colon polyps may be beneficial in select patients, although the data are mixed. Injection of epinephrine prior to polypectomy was reported to reduce the incidence of immediate post-polypectomy bleeding, although there was no demonstrated effect on delayed bleeding. It has been suggested that postprocedure bleeding rates of greater than 1% should prompt evaluation of whether inappropriate practices are being used.

**POSTPOLYPECTOMY ELECTROCOAGULATION SYNDROME**

Postpolypectomy electrocoagulation syndrome is the result of electrocoagulation injury to the bowel wall that induces a transmural burn and localized peritonitis without evidence of perforation on radiographic studies. The reported incidence of this complication varies widely from 3 per 100,000 (0.003%) to 1 in 1000 (0.1%).

Typically, patients with postpolypectomy electrocoagulation syndrome present 1 to 5 days after colonoscopy with fever, localized abdominal pain, localized peritoneal signs, and leukocytosis. It is important to recognize this entity because it does not require surgical treatment. Post-polypectomy electrocoagulation syndrome usually is managed with intravenous hydration, broad-spectrum parenteral antibiotics, and nothing by mouth until the symptoms subside. Successful outpatient management with oral antibiotics has also been reported.

**MORTALITY**

Death has been rarely reported in relation to colonoscopy, with or without polypectomy. In a 2010 review of colonoscopy complications based on prospective studies and retrospective analyses of large clinical or administrative databases, there were 128 deaths reported among 371,099 colonoscopies, for an unweighted pooled death rate of 0.03%. All studies reported mortality within 30 days of the colonoscopy, although some reported all-cause mortality whereas others limited their analysis to colonoscopy-specific mortality. Those reporting all-cause mortality include 116 deaths among 176,834 patients (0.07%). Among those reporting colonoscopy-specific mortality, there were 19 deaths among 284,097 patients (0.007%).

**INFECTION**

Transient bacteremia after colonoscopy, with or with polypectomy, occurs in approximately 4% of procedures, with a range of 0% to 25%. However, signs or symptoms of infection are rare. Although individual cases of infection after colonoscopy have been reported, there is no definite causal link with the endoscopic procedure and no proven benefit for antibiotic prophylaxis. Therefore, current guidelines from the American Heart Association and ASGE recommend against antibiotic prophylaxis for patients undergoing colonoscopy. A 2008 review reported that subsequent to the 2003 Multisociety Guideline for Reprocessing of Flexible GI Endoscopes, all reported cases of transmission of infection resulted from defective equipment and/or failure to adhere to reprocessing guidelines. The Multisociety Guideline for Reprocessing of Flexible GI Endoscopes was updated most recently in 2011.

**GAS EXPLOSION**

Explosive complications of colonoscopy are rare, but they have serious consequences. A 2007 review reported 9 cases, each resulting in colonic perforation and, in one case, death. Gas explosion can occur when combustible levels of hydrogen or methane gas are present in the colonic lumen, oxygen is present, and electrosurgical energy is used (eg, electrocautery or argon plasma coagulation). Suspected risk factors are use of nonabsorbable or incompletely absorbable carbohydrate preparations, such as mannitol, lactulose, or sorbitol, and incomplete colonic cleansing either because a sigmoidoscopy preparation was used (eg, enemas) or because the result of a colonoscopic purge preparation was inadequate. Some authors have advocated use of carbon dioxide during colonoscopy as a preventive measure.

**ABDOMINAL PAIN OR DISCOMFORT**

Less severe, but more common, sequelae of colonoscopy are also important and can impact patient adherence to future colonoscopy. The most commonly reported minor complications of colonoscopy are bloating (25%) and abdominal pain and/or discomfort 5% to 11%. Appropriate techniques, such as avoiding and reducing endoscope looping and minimizing air insufflation should help reduce these symptoms. In addition, randomized trials have demonstrated less postprocedure pain with carbon dioxide compared with standard air insufflation. A water immersion technique that avoids air insufflation also

---

The site of active bleeding can be identified endoscopically, through red blood cell nuclear scintigraphy, or angiographically. Acute postpolypectomy hemorrhage often is immediately apparent and amenable to endoscopic therapy. Nonendoscopic treatment modalities include angiographic embolization and surgery.

Using mini-snare resection without electrocautery instead of hot-biopsy forceps for removal of diminutive polyps may reduce bleeding. The prophylactic use of mechanical methods, such as clips or detachable snares has been reported. A randomized, controlled trial of prophylactic, detachable snare placement prior to polypectomy in 89 patients with large, pedunculated polyps found a significant reduction in bleeding in the detachable snare group (0% vs 12%). The placement of endoscopic clips after removal of colon polyps may be beneficial in select patients, although the data are mixed. Injection of epinephrine prior to polypectomy was reported to reduce the incidence of immediate post-polypectomy bleeding, although there was no demonstrated effect on delayed bleeding. It has been suggested that postprocedure bleeding rates of greater than 1% should prompt evaluation of whether inappropriate practices are being used.

**POSTPOLYPECTOMY ELECTROCOAGULATION SYNDROME**

Postpolypectomy electrocoagulation syndrome is the result of electrocoagulation injury to the bowel wall that induces a transmural burn and localized peritonitis without evidence of perforation on radiographic studies. The reported incidence of this complication varies widely from 3 per 100,000 (0.003%) to 1 in 1000 (0.1%).

Typically, patients with postpolypectomy electrocoagulation syndrome present 1 to 5 days after colonoscopy with fever, localized abdominal pain, localized peritoneal signs, and leukocytosis. It is important to recognize this entity because it does not require surgical treatment. Post-polypectomy electrocoagulation syndrome usually is managed with intravenous hydration, broad-spectrum parenteral antibiotics, and nothing by mouth until the symptoms subside. Successful outpatient management with oral antibiotics has also been reported.

**MORTALITY**

Death has been rarely reported in relation to colonoscopy, with or without polypectomy. In a 2010 review of colonoscopy complications based on prospective studies and retrospective analyses of large clinical or administrative databases, there were 128 deaths reported among 371,099 colonoscopies, for an unweighted pooled death rate of 0.03%. All studies reported mortality within 30 days of the colonoscopy, although some reported all-cause mortality whereas others limited their analysis to colonoscopy-specific mortality. Those reporting all-cause mortality include 116 deaths among 176,834 patients (0.07%). Among those reporting colonoscopy-specific mortality, there were 19 deaths among 284,097 patients (0.007%).

**INFECTION**

Transient bacteremia after colonoscopy, with or with polypectomy, occurs in approximately 4% of procedures, with a range of 0% to 25%. However, signs or symptoms of infection are rare. Although individual cases of infection after colonoscopy have been reported, there is no definite causal link with the endoscopic procedure and no proven benefit for antibiotic prophylaxis. Therefore, current guidelines from the American Heart Association and ASGE recommend against antibiotic prophylaxis for patients undergoing colonoscopy. A 2008 review reported that subsequent to the 2003 Multisociety Guideline for Reprocessing of Flexible GI Endoscopes, all reported cases of transmission of infection resulted from defective equipment and/or failure to adhere to reprocessing guidelines. The Multisociety Guideline for Reprocessing of Flexible GI Endoscopes was updated most recently in 2011.

**GAS EXPLOSION**

Explosive complications of colonoscopy are rare, but they have serious consequences. A 2007 review reported 9 cases, each resulting in colonic perforation and, in one case, death. Gas explosion can occur when combustible levels of hydrogen or methane gas are present in the colonic lumen, oxygen is present, and electrosurgical energy is used (eg, electrocautery or argon plasma coagulation). Suspected risk factors are use of nonabsorbable or incompletely absorbable carbohydrate preparations, such as mannitol, lactulose, or sorbitol, and incomplete colonic cleansing either because a sigmoidoscopy preparation was used (eg, enemas) or because the result of a colonoscopic purge preparation was inadequate. Some authors have advocated use of carbon dioxide during colonoscopy as a preventive measure.

**ABDOMINAL PAIN OR DISCOMFORT**

Less severe, but more common, sequelae of colonoscopy are also important and can impact patient adherence to future colonoscopy. The most commonly reported minor complications of colonoscopy are bloating (25%) and abdominal pain and/or discomfort 5% to 11%. Appropriate techniques, such as avoiding and reducing endoscope looping and minimizing air insufflation should help reduce these symptoms. In addition, randomized trials have demonstrated less postprocedure pain with carbon dioxide compared with standard air insufflation. A water immersion technique that avoids air insufflation also
may reduce pain, especially in the setting of minimal or no sedation.\textsuperscript{78-79}

**MISCELLANEOUS COMPLICATIONS**

Miscellaneous complications of colonoscopy include splenic rupture,\textsuperscript{80-81} acute appendicitis,\textsuperscript{82} diverticulitis,\textsuperscript{2} subcutaneous emphysema,\textsuperscript{83-84} and tearing of mesenteric vessels with intraabdominal hemorrhage. Chemical colitis may occur if glutaraldehyde, used during disinfection, has not been adequately rinsed from the endoscope.\textsuperscript{85}

**COMPLICATIONS ASSOCIATED WITH SPECIFIC COLONOSCOPIC INTERVENTIONS**

**Colonoscopic tattooing**

When a lesion requires marking to aid localization for surgical removal or endoscopic follow-up, a permanent dye is injected to tattoo the colon adjacent to the lesion.\textsuperscript{86} Use of sterile and appropriately diluted solutions has a low rate (0.2\%) of complications.\textsuperscript{87}

**Colonic dilation**

Colonic dilation has been used to treat benign strictures at surgical anastomoses and those associated with Crohn’s disease.\textsuperscript{88} Two prospective studies with a total of 42 patients with anastomotic strictures not from Crohn’s disease reported no complications after dilation.\textsuperscript{89,90} In contrast, a systematic review of 13 studies with 347 patients with Crohn’s disease with colonic strictures reported dilation-related complication rates of 0\% to 18\%, with a pooled complication rate of 2\%.\textsuperscript{91} Almost all complications were perforations.

**Colonic stent placement**

Three pooled analyses of 29 to 88 retrospective studies totaling 598 to 1785 patients have yielded similar results for adverse events in the setting of self-expandable metal stents (SEMS) used for malignant obstruction.\textsuperscript{92-94} The pooled perforation rates ranged from 3.7\% to 4.5\%. The pooled stent migration rates ranged from 9.8\% to 11.8\%, and the stent occlusion rates ranged from 7.3\% to 12\%. Dilation before or immediately after stent placement is not recommended because of the increased perforation risk.\textsuperscript{98} Since the publication of the pooled analyses, 3 randomized, controlled trials of SEMS compared with surgery were closed early because of high rates of complications in the SEMS arms. These complications included 6 perforations and 5 anastomotic leaks among 47 participants,\textsuperscript{95} 3 perforations among 11 participants,\textsuperscript{96} and 2 perforations among 50 participants (of whom only 14 had a stent placed; ie, 47\% technical success rate).\textsuperscript{97} In contrast, a randomized, controlled trial of SEMS as a bridge to surgery (N = 24 in the SEMS arm) reported no stent-related complications.\textsuperscript{98} The difference in estimated complication rates among the studies may be related to patient population, endoscopist experience, and study design.

**Colon decompression tube placement**

The studies examining colon decompression tube outcomes are limited in size. In 3 series consisting of 139 patients with colonic obstruction, one perforation was reported.\textsuperscript{99,100} A series of 50 patients with pseudo-obstruction who underwent 62 colonoscopies with 54 decompression tube placements included one perforation (2\% per-patient rate) and an in-hospital mortality rate of 30\%, reflecting the underlying comorbidities of patients with pseudo-obstruction.\textsuperscript{101}

**Percutaneous endoscopic colostomy**

Percutaneous endoscopic colostomy has been used to treat slow-transit constipation, recurrent sigmoid volvulus, colonic pseudo-obstruction, and neurogenic bowel in patients refractory to other interventions and considered poor surgical candidates.\textsuperscript{88} Series of percutaneous endoscopic colostomy report major complications in 5\% to 12\% (mostly peritonitis), with a 3\% to 7\% rate of procedure-related mortality.\textsuperscript{102-105} Minor complications, such as site infection, buried bumper, and abdominal wall bleeding, exceeded 30\% in the only prospective series.\textsuperscript{103} Most reports describe an all-cause in-hospital mortality rate exceeding 25\%, reflecting the often frail patients who populate these series.\textsuperscript{103-105}

**Colonoscopic hemostasis**

General descriptions of hemostasis techniques, efficacy, and safety are discussed in a 2009 American Society for Gastrointestinal Endoscopy Technology Status Evaluation Report.\textsuperscript{39} The use of any hemostatic technique can initially worsen bleeding, but frequently this can be successfully treated by additional application of the same device or use of another hemostatic device. Colonic perforation is a rare complication of endoscopic hemostasis. However, among patients undergoing treatment of angiectasia, particularly in the right colon, perforation has been reported in up to 2.5\% of cases.\textsuperscript{106} The rare complication of gas explosion during use of argon plasma coagulation is discussed earlier.

**Foreign body removal**

Colorectal foreign bodies are primarily the result of objects inserted per rectum or swallowed (eg, bones, toothpicks).\textsuperscript{107} There also are case reports of migration of extraintestinal foreign bodies into the large intestine (eg, intrauterine contraceptive devices\textsuperscript{108} and inguinal hernia mesh\textsuperscript{109}). A foreign body may cause colonic obstruction. Perforation is a primary concern; the perforation rate likely varies considerably with the type of object (eg, sharp vs blunt) and traumatic versus nontraumatic insertion.\textsuperscript{107} In the case of body packing, that is, transporting illegal drugs by swallowing or inserting plastic bags or condoms filled
with the drug, there is the additional risk of rupture of the bag/condom during attempted removal. This can lead to systemic absorption of the drug, overdose, and, potentially, death. Therefore, it is recommended that endoscopic removal of drug-containing packets should not be attempted.

Prior to any attempted removal of a foreign body, an abdominal plain film to evaluate for free air is recommended. In a series of 83 episodes of a rectal foreign body in 87 patients, 74% were successfully removed nonoperatively.

**Advanced techniques for colonoscopic tissue removal**

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are advanced techniques used to remove suspected premalignant and early stage malignant lesions. As with standard polypectomy, bleeding and perforation are the most common complications with EMR and ESD, but they occur more frequently with these advanced techniques. The reported complication rates vary. Lesion size, location, and histology and operator experience may all contribute to this variability.

The intraprocedural bleeding rate is over 10% in several large series, with delayed bleeding reported in 1.5% to 14% of cases. Bleeding complications are usually endoscopically manageable, although the need for transfusions has been reported. Perforation complicates approximately 5% to 10% of colonic ESD resections and, less commonly, complicates EMR resections (0%-5%). The majority of perforations are recognized at the time of the procedure and are usually successfully managed with endoscopic clip closure.

**CONCLUSION**

Complications are inherent in the performance of colonoscopy. As endoscopy assumes a more therapeutic role in the management of GI disorders, the potential for complications will likely increase. Knowledge of potential endoscopic complications, their expected frequency, and the risk factors associated with their occurrence may help to minimize the incidence of complications. Endoscopists are expected to carefully select patients for the appropriate intervention, be familiar with the planned procedure and available technology, and be prepared to manage any adverse events that may arise. Once a complication occurs, early recognition and prompt intervention will minimize the morbidity and mortality associated with that complication. Review of complications as part of a continuing quality improvement process may serve to educate endoscopists, help to reduce the risk of future complications, and improve the overall quality of endoscopy.

**DISCLOSURE**

D. Fisher is a consultant for Epigenomics. P. Malpas is a consultant for Olympus America. J. Dominitz is a consultant for Epigenomics and Salix Pharmaceuticals. B. Casb is a consultant for Salix Pharmaceuticals. J. Evans is a consultant for Cook Medical. G. Decker is a consultant for Facet Biotechnology. No other financial relationships relevant to this publication were disclosed.

Abbreviations: CORI, Clinical Outcomes Research Initiative; ESD, endoscopic submucosal dissection; SEMS, self-expandable metal stent.

**REFERENCES**

Complications of colonoscopy


